Preclinical efficacy of thioxanthone SR271425 against transplanted solid tumors of mouse and human origin

Investigational New Drugs

Volumn 17, Issue 1, 1999, Pages 17-27

  Corbett, Thomas H ^a,f   Panchapor, Chiab ^a   Polin, Lisa ^a   Lowichik, Nancy ^a   Pugh, Susan ^a   White, Kathryn ^a   Kushner, Juiwanna ^a   Meyer, Jennifer ^a   Czarnecki, Jennifer ^a   Chinnukroh, Salina ^a   Edelstein, Matthew ^a   LoRusso, Patricia ^a   Heilbrun, Lance ^a   Horwitz, Jerome P ^a   Grieshaber, Charles ^b   Perni, Robert ^b   Wentland, Mark ^c   Coughlin, Susan ^d   Elenbaas, Steven ^e   Philion, Richard ^e   Rake, James ^e   more..

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

^c Research Rensselaer Polytechnic Institute   (United States)

^d SANOFI   (France)

^e Sanofi Pharmaceuticals Inc   (United States)

^f NONE   (United States)

Author keywords

Antitumor; Preclinical; SR271425; Thioxanthone

Indexed keywords

SR 271425; THIOXANTHENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL NEOPLASM; HUMAN; LUNG CANCER; MELANOMA; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; HUMANS; MICE; MICE, INBRED ICR; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PACLITAXEL; THIOXANTHENES;

EID: 0032847951     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006267517726     Document Type: Article

References (17)

1. Horwitz J, Massova I, Wiese TE, Bessler BH, Corbett TH: Comparative molecular field analysis of the antitumor activity of 9H-thioxanthen-9-ones against pancreatic ductal carcinoma. J Med Chem 37: 781-786, 1994
2. Wentland MP, Perni RB, Powles RG, Hlavac AG, Mattes KC, Corbett TH, Coughlin SA, Rake JB: Anti-solid tumor efficacy and preparation of N-[[1-[[2-diethylamino)ethyl]amino]-9-oxo-9H-thioxanthen-4-yl]methyl] methanesulfonamide (WIN 33377) and related derivatives. Bioorganic and Medicinal Chemistry Letters 4(4): 609-614, 1994
3. Corbett T, Valeriote F, Baker L et al.: Antitumor activity of N-[[1-[[2-diethylamino)ethyl]amino]-9-oxo-9H-thioxanthen- 4-yl]methyl]methanesulfon-amide (WIN33377) and analogs. Expert Opinion on Investigational Drugs 3(12): 1281-1292, 1994
4. Corbettt T, Valeriote F, LoRusso P et al.: Tumor models and the discovery and secondary evaluation of solid tumor active agents. International J. of Pharmacognosy (Suppl) 33: 102-122, 1995
5. Wentland MP, Perni RB, Huang JI, Powles RG, Aldous SC, Klingbeil KM, Peverly AD, Robinson RG, Corbett T, Jones JL, Rake JB, Coughlin SA: Cyclic variations of SR233377 (WIN33377) and effects on antitumor activity. Bioorganic and Medicinal Chemistry Letters 6: 1345-1350, 1996
6. Corbett TH, Valeriote FA, Demchik L, Lowichik N, Polin L, Panchapor C, Pugh S, White K, Kushner J, Rake J, Wentland M, Golakoti T, Hetzel C, Ogino J, Patterson G, Moore R: Discovery of Cryptophycin-1 and BCN-183577: Examples of strategies and problems in the detection of antitumor activity in mice. Invest New Drugs 15: 207-218, 1997
7. LoRusso PM, Foster BJ, Wozniak A, Graham M, Purvis J, Rake J, Lockwood G, Valdivieso M: Phase I pharmacokinetic study of the novel antitumor agent SW33377 given every 28 days. AACR 36: 1148, 1996
8. Perni R, Wentland MP, Huang JI, Powles RG, Aldous S, Klingbeil KM, Peverly AD, Robinson RG, Corbett TH, Jones JL, Mattes KC, Rake JB, Coughlin SA: Synthesis and antitumor activity of 4-Aminomethylthioxanthenone and 5-Aminomethylbenzothiopyranoindazol derivatives. J Med Chem 41: 3645-3654, 1998
9. Foster BJ, Wiegand RA, Pugh S, LoRusso PM, Corbett TH: Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity. Clin Cancer Res 3: 2047-2053, 1997
10. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP, Jr Schabel FM, Jr: Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 44: 717-726, 1984
11. Polin L, Valeriote F, White K, Panchapor C, Pugh S, Knight J, LoRusso P, Hussain M, Liversidge E, Shaw M, Golakoti T, Patterson G, Moore R, Corbett TH: Treatment of human prostate tumors in PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. Invest New Drugs 15: 99-108, 1997
12. Corbett T, Valetiote F, LoRusso P et al.: In vivo methods for screening and preclinical testing; use of rodent solid tumors for drug discovery. In: Teicher B (Ed), Chapter 5, pp 75-99, Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. Humana Press Inc., Totowa, NJ, 1997
13. Corbett TH: A selective two-tumor soft agar assay for drug discovery. AACR 25: 325, 1984
14. Corbett TH, Valeriote FA, Polin L et al.: Discovery of solid tumor active agents using a soft-agar-colony-formation disk-diffusion-assay. In: Valeriote FA, Corbett TH, Baker LH (Eds), pp 33-87, Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development. Kluwer Academic Publishers, Boston/Dordreact/London, 1992
15. LoRusso PM, Wozniak AJ, Polin L, Capps D, Leopold WR, Werbel LM, Biernat L, Dan ME, Corbett TH: Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Res 50: 4900-4905, 1990
16. Lee J-S, Paull K, Alvarez M, Hose C, Monks A, Fojo AT, Bates SE: Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Molecular Pharmacology 46: 627-638, 1994
17. Coughlin SA, Danz DW, Klingbel KM, Robinson RG, Perni RB, Wentland MP, Rake JB: Mechanism of action of 4-Aminomethyl-thoxanthen-9-one anti-solid tumor agents. AACR 34: 381, 1993